Uptake and Mutagenicity of Moderately Soluble Hexavalent Chromium

中等溶解度六价铬的吸收和致突变性

基本信息

  • 批准号:
    7491192
  • 负责人:
  • 金额:
    $ 18.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-09-01 至 2011-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hexavalent chromium (Cr(VI)) is a known human lung carcinogen. Millions of workers are exposed to Cr(VI) worldwide. The most recent paradigm proposes that the chromate compounds that are moderately water-soluble are more carcinogenic than the chromates that are either insoluble or water-soluble; however, it is not understood why this is so. Most of the data on how chromium damages DNA and causes DNA mutations has come from either the insoluble chromates or the water soluble chromates, not from the moderately soluble chromates that may be the most carcinogenic. The moderately soluble chromates are zinc chromate, strontium chromate and calcium chromate. Several crucial pieces of information are lacking regarding the activity of these moderately soluble chromates. No mutagenicity studies have been carried out with these compounds in human lung epithelial cells, which are the target cells for tumor formation. The types of mutations that these compounds cause have not been characterized in any cell line. The relative mutagenic potency of these chromates is not known. The extent to which these compounds dissolve outside of cells or enter cells as particulates is not known. The involvement of the zinc, strontium and calcium counterions in chromate toxicity is not known. The goals of the current proposal are to explain (1) how the moderately soluble Cr(VI) compounds enter cells and (2) if the mutations caused by the moderately soluble chromates differ from those caused by the soluble and insoluble chromates. The first aim of this proposal will apply the techniques of inductively coupled plasma mass spectrometry, laser scanning confocal microscopy, transmission electron microscopy, and scanning electron microscopy to determine how the moderately soluble chromates enter cells. The second aim of this proposal will measure and characterize mutations at the hypoxanthine (guanine) phosphoribosyl transferase (hprt) locus caused by the moderately soluble chromates in human lung epithelial cells and will compare mutation frequency and identity with mutations caused by the soluble and insoluble chromates. Data from these experiments will determine the relative mutagenic potency of these chromates, and will give insight into mechanisms of action, i.e., involvement of counterion and possible DNA lesions responsible for the mutations. Data from this proposal will provide mode of action information that will be necessary for thorough human risk assessment. The purpose of this work is to determine how chromium(VI) causes cancer. The goals of this proposal are to explain (1) how the moderately soluble chromium(VI) compounds enter cells and (2) if the mutations caused by the moderately soluble chromates differ from those caused by the less carcinogenic soluble and insoluble chromates. Understanding the mode of action of these chromates will provide a foundation for human risk assessment.
描述(由申请人提供):六价铬(Cr(VI))是一种已知的人类肺癌致癌物。全世界数以百万计的工人暴露于铬(六)。最近的范式提出,适度水溶性的铬酸盐化合物比不溶性或水溶性的铬酸盐更具有致癌性;然而,目前还不清楚为什么会这样。大多数关于铬如何破坏DNA并导致DNA突变的数据来自不溶性铬酸盐或水溶性铬酸盐,而不是来自可能最致癌的中溶性铬酸盐。中溶性铬酸盐有铬酸锌、铬酸锶和铬酸钙。关于这些中等可溶性铬酸盐的活性,缺少几个关键的信息。这些化合物尚未在人肺上皮细胞(肿瘤形成的靶细胞)中进行致突变性研究。这些化合物引起的突变类型尚未在任何细胞系中得到表征。这些铬酸盐的相对诱变效力尚不清楚。这些化合物在细胞外溶解或以颗粒形式进入细胞的程度尚不清楚。锌、锶和钙反离子在铬酸盐毒性中的作用尚不清楚。当前提案的目标是解释(1)中溶性铬(VI)化合物如何进入细胞和(2)中溶性铬酸盐引起的突变是否与可溶性和不溶性铬酸盐引起的突变不同。本提案的第一个目标将应用电感耦合等离子体质谱,激光扫描共聚焦显微镜,透射电子显微镜和扫描电子显微镜技术来确定中等可溶性铬酸盐如何进入细胞。本研究的第二个目标是测量和表征中等可溶性铬酸盐在人肺上皮细胞中引起的次黄嘌呤(鸟嘌呤)磷酸核糖基转移酶(hprt)位点上的突变,并将其与可溶性和不溶性铬酸盐引起的突变的频率和特性进行比较。来自这些实验的数据将确定这些铬酸盐的相对诱变效力,并将深入了解作用机制,即反离子的参与和可能导致突变的DNA损伤。该提案的数据将提供行动方式信息,这将是对人类风险进行全面评估所必需的。这项工作的目的是确定铬(VI)是如何致癌的。本提案的目标是解释(1)中溶性铬(VI)化合物如何进入细胞;(2)中溶性铬酸盐引起的突变是否与致癌性较低的可溶性和不溶性铬酸盐引起的突变不同。了解这些铬酸盐的作用方式将为人类风险评估提供基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Diane M Stearns其他文献

Diane M Stearns的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Diane M Stearns', 18)}}的其他基金

Investigator Development Core
研究者开发核心
  • 批准号:
    10207308
  • 财政年份:
    2017
  • 资助金额:
    $ 18.13万
  • 项目类别:
Investigator Development Core
研究者开发核心
  • 批准号:
    10207300
  • 财政年份:
    2017
  • 资助金额:
    $ 18.13万
  • 项目类别:
Developmental Core
发展核心
  • 批准号:
    8323497
  • 财政年份:
    2011
  • 资助金额:
    $ 18.13万
  • 项目类别:
CELLULAR GENOTOXICITY OF PHOTOACTIVATED URANIUM
光活化铀的细胞遗传毒性
  • 批准号:
    8036952
  • 财政年份:
    2010
  • 资助金额:
    $ 18.13万
  • 项目类别:
Developmental Core
发展核心
  • 批准号:
    7847137
  • 财政年份:
    2009
  • 资助金额:
    $ 18.13万
  • 项目类别:
Uptake and Mutagenicity of Moderately Soluble Hexavalent Chromium
中等溶解度六价铬的吸收和致突变性
  • 批准号:
    7297241
  • 财政年份:
    2007
  • 资助金额:
    $ 18.13万
  • 项目类别:
Comprehensive NAU/AZCC Cancer Research Partnership
NAU/AZCC 癌症研究综合合作伙伴关系
  • 批准号:
    7115367
  • 财政年份:
    2002
  • 资助金额:
    $ 18.13万
  • 项目类别:
Comprehensive NAU/AZCC Cancer Research Partnership
NAU/AZCC 癌症研究综合合作伙伴关系
  • 批准号:
    7691872
  • 财政年份:
    2002
  • 资助金额:
    $ 18.13万
  • 项目类别:
Comprehensive NAU/AZCC Cancer Research Partnership
NAU/AZCC 癌症研究综合合作伙伴关系
  • 批准号:
    6935408
  • 财政年份:
    2002
  • 资助金额:
    $ 18.13万
  • 项目类别:
Comprehensive NAU/AZCC Cancer Research Partnership
NAU/AZCC 癌症研究综合合作伙伴关系
  • 批准号:
    7500499
  • 财政年份:
    2002
  • 资助金额:
    $ 18.13万
  • 项目类别:

相似国自然基金

Calcium/NFAT/GLUT3通路调控糖酵解代谢在CAR-T细胞耗竭中的作用和机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
miR-30调控Calcium/Calcineurin通路在慢性肾脏病心肌保护中的作用
  • 批准号:
    81670699
  • 批准年份:
    2016
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
水稻OsCAS(Calcium-sensing Receptor)基因的功能分析
  • 批准号:
    30900771
  • 批准年份:
    2009
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

zero-CO2 cemeNt ThRough cArBonation of cAlcium Silicates and aluminateS (Contrabass)
通过硅酸钙和铝酸盐的碳化生产零二氧化碳水泥(Contrabass)
  • 批准号:
    EP/Y030354/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.13万
  • 项目类别:
    Research Grant
CONTRABASS - zero-CO2 cemeNt ThRough cArBonation of cAlcium Silicates and aluminateS
CONTRABASS - 通过硅酸钙和铝酸盐碳化生产的零二氧化碳水泥
  • 批准号:
    EP/Y031989/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.13万
  • 项目类别:
    Research Grant
NSF Convergence Accelerator Track M: A new biomanufacturing process for making precipitated calcium carbonate and plant-based compounds that support human health
NSF Convergence Accelerator Track M:一种新的生物制造工艺,用于制造支持人类健康的沉淀碳酸钙和植物基化合物
  • 批准号:
    2344228
  • 财政年份:
    2024
  • 资助金额:
    $ 18.13万
  • 项目类别:
    Standard Grant
DEL-1 Promotes Biogenesis of Mineralizing Extracellular Vesicles by Mediating Intracellular Calcium Signaling
DEL-1 通过介导细胞内钙信号传导促进矿化细胞外囊泡的生物合成
  • 批准号:
    24K19876
  • 财政年份:
    2024
  • 资助金额:
    $ 18.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The development of targeterd therapies for Intra-mitochondrial calcium ion dinamics in colorectal cancer stem cells
结直肠癌干细胞线粒体内钙离子动态靶向疗法的开发
  • 批准号:
    23K06654
  • 财政年份:
    2023
  • 资助金额:
    $ 18.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Muscle contraction and calcium signaling
肌肉收缩和钙信号传导
  • 批准号:
    23K10634
  • 财政年份:
    2023
  • 资助金额:
    $ 18.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
RUI: Allosteric Activators of the Sarco/Endoplasmic Reticulum Calcium ATPase
RUI:肌瘤/内质网钙 ATP 酶的变构激活剂
  • 批准号:
    2327946
  • 财政年份:
    2023
  • 资助金额:
    $ 18.13万
  • 项目类别:
    Standard Grant
Understanding the cellular response to calcium influx based on endoplasmic reticulum-mitochondria interaction
基于内质网-线粒体相互作用了解细胞对钙流入的反应
  • 批准号:
    22KJ3086
  • 财政年份:
    2023
  • 资助金额:
    $ 18.13万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
In vivo calcium imaging during appetitive learning in HIV Tat transgenic mice exposed to cannabis
暴露于大麻的 HIV Tat 转基因小鼠食欲学习过程中的体内钙成像
  • 批准号:
    10696442
  • 财政年份:
    2023
  • 资助金额:
    $ 18.13万
  • 项目类别:
Mitochondrial Calcium and Neuronal Health
线粒体钙和神经元健康
  • 批准号:
    10638869
  • 财政年份:
    2023
  • 资助金额:
    $ 18.13万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了